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While increased levels of high-density lipoprotein (HDL)-cholesterol corre-
late with protection against cardiovascular disease, recent findings demon-
strate that HDL function, rather than HDL-cholesterol levels, may be a
better indicator of cardiovascular risk. One mechanism by which HDL
function can be compromised is through modification by reactive aldehydes
such as acrolein (Acro), 4-hydroxynonenal, and malondialdehyde (MDA).
In this study, we tested the hypothesis that modification of HDL with reac-
tive aldehydes would impair HDL’s athero-protective functions in macro-
phages. Compared to native HDL, Acro- and MDA-modified HDL have
impaired abilities to promote migration of primary peritoneal macrophages
isolated from C57BL6/J mice. Incubation of macrophages with MDA-
HDL also led to an increased ability to generate reactive oxygen species.
Our studies revealed that the changes in HDL function following aldehyde
modification are likely not through activation of canonical nuclear factor-
kappa B signaling pathways. Consistent with this finding, treatment of
either noncholesterol-loaded macrophages or foam cells with modified
forms of HDL does not lead to significant changes in expression levels of
inflammatory markers. Importantly, our data also demonstrate that
changes in HDL function are dependent on the type of modification pre-
sent on the HDL particle. Our findings suggest that modification of HDL
with reactive aldehydes can impair some, but not all, of HDL’s athero-pro-
tective functions in macrophages.
Introduction
Decades of epidemiological studies show that
higher circulating levels of high-density lipoprotein
(HDL)-cholesterol associate with lower risk for car-
diovascular disease (CVD). However, therapeutic
interventions [1] and genetic predisposition [2] that
raise HDL-cholesterol levels have failed to protect
against CVD. These observations have led to the
hypothesis that HDL function, rather than HDL-c-
holesterol levels, may be a better predictor of CVD
risk [3].
Abbreviations
Acro, acrolein; ApoA-I, apolipoprotein A-I; CBA, coumarin-7-boronic acid; COH, 7-hydroxycoumarin; CVD, cardiovascular disease; HDL, high-
density lipoprotein; HNE, 4-hydroxynonenal; IL, interleukin; LDL, low-density lipoprotein; LPS, lipopolysaccharide; MDA, malondialdehyde;
NF-jB, nuclear factor-kappa B; oxLDL, oxidized low-density lipoprotein; PEG, polyethylene glycol; ROS, reactive oxygen species; SFM,
serum-free media.
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Macrophages play a major role in the development
and progression of atherosclerosis. Macrophages
express several scavenger receptors (SR) including SR-
BI and CD36, the primary receptors for HDL [4] and
oxidized low-density lipoprotein (oxLDL) [5], respec-
tively, as well as members of the ATP-binding cassette
(ABC) superfamily of transporters, including ABCA1
and ABCG1. These receptors and transporters play
vital roles in controlling cellular cholesterol levels,
inflammatory responses, and a variety of other macro-
phage processes. Through interactions with CD36,
oxLDL promotes the accumulation of excess esterified
cholesterol in macrophages that results in the forma-
tion of lipid-laden ‘foam cells’ that are the precursor
cells for plaque formation in the arterial wall (reviewed
in [6]). OxLDL can also promote pro-inflammatory
cytokine release, generate reactive oxygen species
(ROS), as well as inhibit macrophage migration that
results in macrophage trapping and eventually promo-
tion of apoptosis (reviewed in [7]).
On the other hand, HDL helps to protect against
CVD. The most commonly studied antiatherogenic
function of HDL is its role in the early stages of the
reverse cholesterol transport pathway, where HDL
mediates the removal of cholesterol from peripheral
macrophages for delivery to the liver for net excretion
[8]. In macrophages, HDL also protects against the
generation of ROS [9] and promotes the production of
anti-inflammatory cytokines [10]. Furthermore, by
interacting with SR-BI, HDL can promote macro-
phage migration [11] and prevent foam cell formation
(reviewed in [6]).
An emerging body of literature suggests that many
of HDL’s cardioprotective functions can become com-
promised in several chronic inflammatory diseases. For
example, HDL isolated from patients with coronary
artery disease has a decreased ability to promote
endothelial nitric oxide synthase activation, nitric
oxide production, and endothelial cell protection when
compared to HDL isolated from control patients [12].
Similarly, HDL from patients with chronic kidney dis-
ease is unable to protect endothelial cells against
monocyte adhesion and triggers a heightened cytokine
response [13]. HDL isolated from lupus patients
induces pro-inflammatory effects in macrophages [14].
In fact, in many of these diseased states, ‘dysfunctional
HDL’ has been proposed as a potential biomarker for
risk of atherosclerosis [15]. However, the mechanisms
responsible for rendering HDL dysfunctional are not
well understood.
One potential mechanism by which HDL can
become dysfunctional is by modification with reactive
carbonyl aldehydes, many of which have been
implicated in various disease states, including
atherosclerosis [16]. Acrolein, 4-hydroxynonenal
(HNE), and malondialdehyde (MDA) are reactive
aldehydes that are found in circulation and play a role
in altering lipoprotein function [17–19]. Furthermore,
the main protein component of HDL, apolipoprotein
A-I (apoA-I), can be modified by these oxidants in
plasma [20] and in isolated human atheroma [21,22].
Recently, our group has shown that modification
of HDL with acrolein (Acro) impairs SR-BI–medi-
ated cholesterol transport [23]. These findings led us
to hypothesize that Acro-modified HDL, and per-
haps other reactive aldehyde-modified forms of
HDL, have pro-atherogenic effects on macrophages.
In this study, we describe how oxidative modification
with three different reactive aldehydes (Acro, HNE,
and MDA) can impair some of HDL’s cardioprotec-
tive functions in macrophages. Further, we demon-
strate that changes in HDL function are dependent
on the type of aldehyde modification present on the
HDL particle.
Results
Reactive aldehydes modify HDL in vitro
To test our hypothesis that a family of reactive aldehy-
des impairs HDL’s cardioprotective functions, we first
confirmed in vitro oxidative modification of HDL, sim-
ilar to what we had shown in our previous studies with
Acro-modified HDL [23]. As shown in Fig. 1, immu-
noblot analyses demonstrated that aldehyde adduct
formation promoted cross-linking of apoA-I. Further-
more, using antibodies that recognize specific adducts
formed by these aldehydes, immunoblot analyses con-
firmed the presence of Acro, HNE, and MDA on the
HDL particles.
Modified HDL inhibits macrophage migration
During the early stages of plaque formation, macro-
phages play a critical role in a variety of pro-athero-
genic pathways. For example, oxLDL inhibits
macrophage migration by promoting macrophage
trapping [24], a process that helps mediate foam cell
formation and pro-inflammatory signaling. On the
other hand, HDL promotes the migration of macro-
phages through an SR-BI–dependent process [11].
Therefore, we performed a Boyden Chamber assay to
determine the impact of aldehyde modification on
HDL’s ability to promote macrophage migration.
Compared to native HDL, both Acro- and MDA-
modified HDL failed to promote macrophage
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migration (Fig. 2). Macrophage migration in the
presence of HNE-HDL was similar to that of native
HDL.
MDA-modified HDL generates reactive oxygen
species in macrophages
Interaction of oxLDL with macrophages generates
intracellular ROS, a step which appears to be critical
to downstream signaling events. To measure ROS gen-
eration, we used a coumarin-7-boronic (CBA) probe,
which is specific for hydrogen peroxide (H2O2) and
peroxynitrite (ONOO) generation. The product
formed is 7-hydroxycoumarin (COH) and was detected
using HPLC methods [25]. Our data demonstrate that,
like oxLDL, incubation with MDA-HDL generated a
1.5-fold increase in COH levels over treatment with
serum-free media (SFM) alone (Fig. 3). Incubation of
acro- or HNE-modified HDL did not lead to statisti-
cally significant increases in ROS generation. To iden-
tify the specific ROS oxidizing the probe following
incubation with MDA-HDL, we measured COH pro-
duction in the presence of polyethylene glycol (PEG)-
catalase, which selectively converts H2O2 to H2O and
O2. Our data showed that in the presence of catalase,
MDA-HDL–induced COH production was suppressed,
demonstrating that H2O2, rather than ONOO
-, is the
major ROS formed by macrophages following treat-
ment with MDA-HDL.
Aldehyde-modified HDL does not activate NF-jB
signaling
When oxLDL interacts with macrophages, several
downstream signaling cascades are activated, including
Fig. 1. Immunoblot analysis verifies apoA-I protein cross-linking and modification of HDL with reactive aldehydes. HDL was incubated with
either 250 µM Acro, 500 µM HNE, or 15 µM MDA for 18 h. The reaction was stopped with a 20-fold excess of aminoguanidine-HCl. HDL
proteins (20 lg total protein) were separated by 4–15% SDS/PAGE and following transfer to a nitrocellulose membrane, proteins were
visualized by immunoblot analysis using antibodies directed against apoA-I or adducts formed by modification with Acro, HNE, or MDA.
Reactive aldehyde structures are shown below each immunoblot. Data are representative of four independent experiments.
Fig. 2. Aldehyde-modified HDL has an impaired ability to mediate
macrophage migration. Murine peritoneal macrophages were
placed on the top of a Boyden Chamber. SFM or SFM containing
native or modified HDL (50 µgmL1) was placed on the bottom of
the well. Following 24 h incubation, the bottom of the membrane
was DAPI-stained and fluorescence quantified. Values represent
four independent experiments (two in the case of MDA-HDL), each
performed in duplicate, with 3–5 fields quantified from each
sample. Values are shown as mean  SEM and normalized to
SFM treatment for comparison. Replicates within individual
experiments are designated by different symbols. Statistical
analyses were determined by one-way ANOVA. ***P < 0.001 vs.
HDL.
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pathways related to nuclear factor-kappa B (NF-jB)
signaling [26]. Additionally, others have reported that
HDL modified by myeloperoxidase can activate NF-
jB signaling [27]. To determine if aldehyde modifica-
tion alters HDL function by activating NF-jB signal-
ing pathways, we measured the phosphorylation status
of p65 in peritoneal macrophages treated with
50 µgmL1 of oxLDL, native HDL or aldehyde-mod-
ified HDL for 0 (SFM), 5, 10, or 30 min incubations
(Fig. 4A,B). Treatment with lipopolysaccharide (LPS)
or TNFa served as positive controls for phosphoryla-
tion of the p65 subunit. As expected, our results
demonstrated that oxLDL was able to stimulate phos-
phorylation of p65. On the other hand, incubation of
macrophages with either native HDL or aldehyde-
modified HDL did not lead to increased phosphoryla-
tion of p65. Additionally, we utilized a THP-1/secreted
alkaline phosphatase reporter cell line to measure NF-
jB activation. These data confirmed that, unlike
oxLDL, none of the aldehyde-modified forms of HDL
activated the reporter line (Fig. 4C), suggesting that
any changes in HDL function in macrophages caused
by aldehyde-modified HDL are through alternative
pathways.
Modified forms of HDL do not promote
inflammation in macrophages or foam cells
Macrophages found in human atherosclerotic plaque
produce a large number of cytokines [28–30]. To deter-
mine if aldehyde-modified HDL affects inflammatory
cytokine production, peritoneal macrophages were
treated with SFM or SFM containing 50 lgmL1 of
oxLDL, HDL, acro-HDL, HNE-HDL, or MDA-HDL
for 6 h. Transcript levels of interleukin (IL)-1b, induci-
ble nitric oxide synthase (iNOS), IL-10, IL-6, and
TNFa were measured using qRT-PCR. Our results
showed that treatment of noncholesterol-loaded
macrophages with oxLDL induced expression of these
cytokines as expected [31–33]. On the other hand,
incubation of macrophages with native HDL, acro-,
HNE-, or MDA-HDL did not result in significant
changes in mRNA levels of any of the measured
inflammatory markers (Fig. 5A–E). Shorter (2 h) or
longer (24 h) incubation times with modified forms of
HDL also revealed no changes in inflammatory mar-
ker expression compared to native HDL (data not
shown). Treatment of cells with LPS or oxLDL served
as positive controls for cytokine production.
High-density lipoprotein can suppress pro-inflamma-
tory cytokine levels in the presence of additional
inflammatory stimuli, such as LPS [34] or oxLDL [35].
To determine if modified HDL can decrease inflamma-
tory cytokine production in foam cells, macrophages
were cholesterol-loaded with 50 lgmL1 oxLDL for
24 h, followed by incubation with SFM or SFM con-
taining 50 lgmL1 oxLDL, HDL, acro-HDL, HNE-
HDL, or MDA-HDL for 6 h and transcript levels of
IL-1b, iNOS, IL-10, IL-6, and TNFa were measured
as previously described (Fig. 5F–J). Similar to the
results seen in noncholesterol-loaded macrophages,
modification of HDL with reactive aldehydes does not
impact inflammatory cytokine expression. Addition-
ally, secreted cytokine levels of IL-1b, TNFa, and IL-6
Fig. 3. MDA-HDL increases ROS generation. Cholesterol-loaded primary peritoneal macrophages were treated with SFM or SFM containing
50 µgmL1 oxLDL, HDL, acro-HDL, HNE-HDL, and MDA-HDL for 1 h at 37 °C  500 UmL1 of polyethylene glycol-catalase. ONOO and/
or H2O2 generation were quantified by measuring the conversion of CBA to COH. Statistical analyses were determined by one-way ANOVA
for comparison of minus catalase samples. ***P < 0.01 vs. HDL in the absence of catalase. Statistical analyses were determined using an
unpaired T-test for +/ catalase experiments. *P < 0.05. Data are the average of at least eight experiments (four in the case
of  polyethylene glycol-catalase addition), each performed in duplicate (each dot represents the average of the duplicates). Values are
shown as mean  SEM.
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were measured by ELISA following 24 h incubation of
foam cells with SFM or SFM containing 50 lgmL1
oxLDL, HDL, acro-HDL, HNE-HDL, or MDA-HDL
(Fig. 6). There were no significant changes in secretion
of IL-1b, TNFa, or IL-6 levels with any of the modi-
fied forms of HDL. To further determine if modified
HDL impacts inflammatory gene expression in the
presence of pro-inflammatory stimuli, we coincubated
primary peritoneal macrophages with 50 lgmL1
oxLDL and 50 lgmL1 native or modified HDL for
2, 6, or 24 h. Our results demonstrated that coincuba-
tion with native HDL or the modified forms of HDL
with oxLDL did not lead to major changes in inflam-
matory gene expression at any of the time points
tested (Fig. 7).
Discussion
Recent studies suggest that enhancing HDL’s cardio-
protective functions, rather than raising circulating
HDL-cholesterol levels, may be a better approach to
reducing CVD risk. However, the circumstances that
govern HDL function are not well understood. In the
current study, we determined that oxidative modifica-
tion of HDL with reactive aldehydes (Acro, HNE or
MDA) alters HDL’s athero-protective functions in
macrophages. Specifically, we demonstrate that HDL
modified by reactive aldehydes has an impaired ability
to promote macrophage migration and promotes ROS
generation, with no impact on inflammatory cytokine
production. Our findings also suggest that changes in
Fig. 4. Aldehyde-modified HDL does not activate NF-jB signaling. (A) Primary peritoneal macrophages were treated with SFM (0 time
points) or SFM containing 50 µgmL1 HDL, acro-HDL, HNE-HDL, or MDA-HDL for 5, 15, or 30 min at 37 °C. Cells were lysed and the level
of phosphorylated p65 was determined by immunoblot analysis. Total p65 levels were measured as a loading control for phosphorylation.
Treatment with oxLDL (50 µgmL1), LPS (100 nM), or TNFa (10 nM) served as positive controls for phosphorylation. Data shown are
representative of four immunoblots. (B) The ratio of phosphorylated p65 to total p65 was measured by densitometry and normalized to SFM
(0 time point). Data are the mean  SEM of four independent experiments. Statistical analyses were determined by two-way ANOVA.
*P < 0.05, **P < 0.001. (C) NF-jB reporter THP-1 cells were treated for 1 h with SFM or SFM containing 50 µgmL1 of HDL, oxLDL, acro-
HDL, HNE-HDL, or MDA-HDL. Media was collected and the secreted reporter protein was measured by reading absorbance at 655 nm.
Treatment with LPS (100 nM) for 1 h served as a positive control. Values are an average of six independent experiments and data are
shown as mean  SEM. Statistical analyses were determined by one-way ANOVA. **P < 0.001 vs. HDL.
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HDL function are dependent on the type of modifica-
tion present on the HDL particle.
The reactive aldehydes tested in this study are physi-
ologically relevant to CVD, and all are products of
lipid peroxidation. Since Acro is a major component
of cigarette smoke and other environmental
atmospheric emissions, exposure to Acro is considered
a CVD risk factor [36]. In mice, Acro consumption
can induce dyslipidemia and modify lipoproteins [17].
In humans, Acro colocalizes with apoA-I in
atherosclerotic plaque [37]. Related aldehydes such as
HNE and MDA have also been implicated in
Fig. 6. Modification of HDL with reactive aldehydes does not alter inflammatory cytokine secretion in foam cells. Primary peritoneal
macrophages, pretreated with 50 µgmL1 oxLDL for 24 h to induce foam cell expression. Next, foam cells were incubated with SFM alone
or SFM containing 50 µgmL1 HDL, acro-HDL, HNE-HDL, or MDA-HDL for 24 h at 37 °C. Foam cells treated with a second incubation of
50 µgmL1 of oxLDL or LPS (100 nM) served as positive controls. Secreted levels of (A) IL-1b, (B) TNFa, and (C) IL-6 were measured by
ELISA. Data are the average of at least three independent experiments and values are shown as mean  SEM. All statistical analyses were
determined by one-way ANOVA. **P < 0.01 vs. HDL.
Fig. 7. Coincubation of oxLDL with native HDL or modified forms of HDL did not lead to major changes in inflammatory gene expression.
Primary peritoneal macrophages were treated with 50 µgmL1 oxLDL in combination with 50 µgmL1 native or modified HDL for 2, 6, or
24 h at 37 °C. Messenger RNA was isolated, converted to cDNA, and (A) IL-1b, (B) iNOS, and (C) IL-10 transcript levels were quantified
using qRT-PCR. Murine b-actin was used as an internal control. Data are presented as a relative fold change to SFM treatment and b-actin
levels. Data are the average of at least three independent experiments and values are shown as mean  SEM. All statistical analyses were
determined by two-way ANOVA. ***P < 0.001 vs. SFM. Treatment with LPS (100 nM) served as positive control.
Fig. 5. Modification of HDL with reactive aldehydes does not alter HDL’s inflammatory properties on macrophages or foam cells. (A–E)
Primary peritoneal macrophages were treated with SFM or SFM containing 50 µgmL1 HDL, acro-HDL, HNE-HDL, MDA-HDL, or oxLDL for
6 h at 37 °C. Messenger RNA was isolated, converted to cDNA, and genes of interest were quantified using qRT-PCR. Murine b-actin was
used as an internal control. Data are presented as a relative fold change to SFM treatment and b-actin levels. Data are the average of at
least four independent experiments. (F-J) Primary peritoneal macrophages were pretreated with 50 µgmL1 oxLDL for 24 h to induce foam
cell expression. Next, foam cells were incubated with SFM alone or SFM containing 50 µgmL1 oxLDL, HDL, acro-HDL, HNE-HDL, or
MDA-HDL for an additional 6 h at 37 °C. Foam cells treated with LPS (100 nM) were used as positive controls. Gene expression was
determined as described in A–C. Data are the average for three independent experiments and values are shown as mean  SEM. All
statistical analyses were determined by one-way ANOVA. *P < 0.05, **P < 0.01, ***P < 0.001 vs. HDL.
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lipoprotein modification. HDL from patients with
acute coronary syndrome or with stable angina carries
both HNE and MDA adducts [20]. When plasma is
exposed to HNE, the activity of lecithin : cholesterol
acyltransferase, an enzyme required for HDL matura-
tion is decreased [38].
The ability of reactive aldehydes to form covalent
crosslinks in proteins has been well studied [39]. In our
study, we demonstrated that modification with reactive
aldehydes leads to apoA-I protein cross-linking on
whole-particle HDL. Shao et al. [40] demonstrated
that the specific lysine residues on apoA-I modified by
Acro are similar between lipid-free apoA-I and whole-
particle HDL [23]. Modification of apoA-I with MDA
also predominantly leads to the modification of lysine
residues 56 and 118 [40]. While HNE can modify lysi-
nes on other proteins, Shao et al. [40] demonstrated
that HNE preferentially targets all five histidine resi-
dues present on apoA-I. To our knowledge, specific
apoA-I residues modified by MDA or HNE on whole-
particle HDL have not been identified. However, all
three aldehydes are present in circulation and have
been shown to modify lipoproteins [17,19,22,37,40–43].
In addition, apoA-II, the second most abundant HDL
apolipoprotein, also presents crosslinked species when
modified by Acro [23], HNE or MDA (data not
shown).
Macrophage trapping is a critical step in the pro-
gression of atherosclerosis. As such, increasing mobi-
lization of macrophages has been proposed as a
therapeutic strategy to reverse atherosclerosis. OxLDL
plays an important role in recruitment and retention
of lipid-laden macrophages within the plaque [24]. On
the other hand, HDL promotes macrophage migration
[11], a process that could ultimately lead to plaque
regression [6]. We demonstrated that, compared to
native HDL, aldehyde-modified HDL could not pro-
mote migration of peritoneal macrophages. It is possi-
ble that aldehyde-modified HDL’s inability to promote
macrophage migration is due to defects in SR-BI–me-
diated signaling cascades that include PI3K and Akt
[11].
Following incubation with oxLDL, macrophages
can produce a variety of different ROS species includ-
ing H2O2 [26]. We measured ROS generation using a
CBA-to-COH probe that is specific for generation of
ONOO- and H2O2 [25]. Like oxLDL, incubation with
MDA-HDL led to increased COH levels. The presence
of polyethylene glycol-catalase prevented COH pro-
duction, demonstrating that the major form of ROS
generated following incubation with MDA-HDL is
H2O2. Future experiments will determine if ROS gen-
eration following incubation of macrophages with
MDA-HDL is primarily through NADPH oxidase.
Our results also demonstrated that only MDA-HDL,
but not acro- or HNE-HDL, lead to increased ROS
generation in peritoneal macrophages. It is possible
that Acro, HNE, and MDA preferentially modify dif-
ferent components of the HDL particle. While our
studies demonstrated that all three aldehydes modify
the protein component of HDL (as in Fig. 1), we can-
not exclude the possibility that these aldehydes also
modify specific HDL lipids. Previous work has shown
that modification of LDL with MDA generates a mod-
ification similar to that of copper-modified LDL [44],
a well-known inducer of lipid peroxidation [45]. There-
fore, perhaps MDA has similar effects on HDL, con-
tributing to the differential effects observed between
different modified HDL species, and this hypothesis
warrants further investigation.
When oxLDL interacts with macrophages, NF-jB
signaling is activated [26]. It has also been suggested
that HDL, too, can activate NF-jB signaling in macro-
phages [27], although others have reported that HDL
inhibits inflammation by suppressing NF-jB signaling
[46]. Interestingly, HDL modified by myeloperoxidase
can activate NF-jB signaling in endothelial cells [27].
One group has reported that while HDL induced
expression of NF-jB reporter genes, HDL did not lead
to nuclear localization of p65 [47], suggesting that
HDL-dependent regulation of NF-jB responses poten-
tially implicates another subunit. Our data suggest that
aldehyde-modified HDL does not activate NF-jB sig-
naling due to lack of phosphorylation of the p65 sub-
unit. As such, any changes to HDL function following
modification are likely through alternative pathways.
Macrophages trapped within an atherosclerotic
lesion have been shown to produce both pro- and
anti-inflammatory cytokines [48]. Previous reports have
shown that treatment of human lung lymphoblasts
with unconjugated HNE (i.e., aldehyde alone) can acti-
vate NF-jB signaling and increase the expression of
IL-8, IL-1b, and TNFa following a 6 h treatment [49].
In contrast, our results showed that modified HDL did
not lead to increased expression of these cytokines in
macrophages at 2, 6, or 24 h. In lipid-loaded macro-
phages, modified HDL also had no impact on inflam-
matory gene expression compared to native HDL.
Additionally, when coincubated with a pro-inflamma-
tory stimuli (oxLDL), modified forms of HDL showed
no significant changes in inflammatory gene expres-
sion. These data suggest that modification of HDL
with reactive aldehydes does not generate a particle
with pro-inflammatory properties.
One interesting observation from our studies is that
changes to HDL function were dependent on the type
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of modification present on the particle, suggesting that
not all types of modified HDL behave similarly. HDL
is comprised of a large variety of lipids and proteins,
and HDL species vary by size and shape. Thus, one
potential contributor to differences in function with
aldehyde-modified HDL could be the aldehyde’s pre-
ferred target of modification. While our analysis of
HDL modification was limited to detection of protein
cross-linking, it is possible that some reactive aldehy-
des preferentially modify nonprotein components of
HDL. Additionally, the majority of our studies was
performed using primary peritoneal macrophages that
were isolated from mice 4 days postinjection with 4%
thioglycolate, a model system that has been routinely
used for studies of lipoprotein metabolism [9,50–54].
We chose thioglycolate-elicited macrophages for our
studies for several reasons. Firstly, we can isolate these
cells in large quantities. Secondly, because primary
peritoneal macrophages replicate at minimal levels
[55], they serve as an ideal cell system for our migra-
tion studies. However, macrophages elicited by thiogly-
colate can have altered responses when compared to
resident macrophages [56,57]. Therefore, confirmation of
our data using alternative sources of macrophages,
including murine resident peritoneal macrophages, mur-
ine bone marrow-derived macrophages, or human mono-
cyte-derived macrophages is warranted.
Recent failures in HDL-raising therapies to provide
cardiovascular benefit have led to the conclusion that we
have much to learn about HDL’s cardioprotective func-
tions in the body. Understanding the impact of modifica-
tion with reactive aldehydes on HDL function will help
in developing new therapeutic approaches aimed at pre-
venting HDL dysfunction and enhancing HDL’s cardio-
protective functions in the fight against CVD.
Materials and methods
1,1,3,3-Tetramethoxypropane for MDA generation, LPS,
and catalase-polyethylene glycol were purchased from
Sigma-Aldrich (Saint Louis, MO, USA). Boyden chambers
(6.5 mm insert, 5.0 µm polycarbonate membrane) were
from Costar (Burlington, MA, USA) (3421). HNE was
purchased from Cayman Chemicals (Ann Arbor, MI,
USA). Acrolein was purchased from Ultra Scientific (North
Kingstown, RI, USA). Aminoguanidine hydrochloride was
purchased from Acros Organics (Morris Plains, NJ, USA).
The CBA probe was generously provided by Balaraman
Kalyanaraman, PhD (Free Radical Research Center, Medi-
cal College of Wisconsin). ELISA kits for IL-1b, IL-6, and
TNFa were from Invitrogen (Carlsbad, CA, USA). Human
LDL (1 mgmL1) was purchased from Lee BioSolutions
(Maryland Heights, MO, USA). Human HDL
(10 mgmL1), purified via sequential high-speed ultracen-
trifugation (density = 1.063–1.21 gmL1), was purchased
from Alfa Aesar (Ward Hill, MA, USA). It consists of 60–
70% apoA-I, 20% apoA-II and 7–8% (or less) apoE. HDL
preps contain ~ 55% protein, 3–15% triglycerides, 26–46%
phospholipids, 15–30% cholesteryl esters and 2–10% free
cholesterol. The following antibodies were used: Anti-Apo-
AI (Santa Cruz Biotechnology, Dallas, TX, USA), anti-
HNE Michael adducts (Thermo Fisher Scientific, Waltham,
MA, USA) anti-MDA (Abcam, Cambridge, UK), anti-
Acro (Abcam), anti-rabbit IgG (Amersham-GE Healthcare,
Pittsburgh, PA, USA), anti-mouse IgG (Amersham-GE
Healthcare), phospho-p65 at residue Ser536 (Cell Signaling,
Danvers, MA, USA) and total p65 (Cell Signaling). All
other reagents were of analytical grade.
Lipoproteins and their chemical modification
Native HDL (1 mgmL1) was incubated with 500 lM
HNE, 250 lM Acro, or 15 lM MDA at 37 °C for 18 h.
MDA was made prior to each experiment as previously
described [40]. Each reaction was stopped by adding 20-
fold molar excess of aminoguanidine hydrochloride to scav-
enge excess aldehyde, and experimental assays were per-
formed immediately. LDL was oxidized by dialysis against
5 µM CuSO4 in PBS for 6 h at 37 °C. Oxidation was termi-
nated by dialysis against PBS containing 0.54 mM EDTA
overnight at 4 °C, and for another 6 h at 4 °C against PBS
to eliminate remaining EDTA.
Animals and primary cell culture
All experimental procedures in mice conformed to the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH publi-
cation, 8th Edition, 2011) and all procedures were carried
out according to protocols approved by the Institutional
Animal Care and Use Committee of the Medical College of
Wisconsin.
Wild-type C57BL6/J mice (~ 50 in total) were housed
under a normal light–dark cycle and bred in a pathogen-
free barrier facility in accordance with federal and institu-
tional guidelines. At the time of macrophage isolation, mice
were euthanized by CO2 inhalation followed by cervical
dislocation. Peritoneal macrophages were isolated as previ-
ously described [37]. Briefly, on day 4 following a 4% thio-
glycolate injection, male or female mice (8–12 weeks of
age) were euthanized via CO2 inhalation followed by cervi-
cal dislocation, and macrophages were isolated in PBS, cen-
trifuged at 400 g for 10 min at 4 °C, and resuspended in
complete RPMI media (RPMI 1640 containing 10% FBS,
2 mM L-glutamine, 50 unitsmL1 penicillin, 50 µgmL1
streptomycin, and 1 mM sodium pyruvate), with the excep-
tion of macrophages used for migration studies, which were
703The FEBS Journal 287 (2020) 695–707 ª 2019 Federation of European Biochemical Societies
R. L. Schill et al. Modification of HDL with reactive aldehydes
resuspended in RPMI lacking serum and antibiotics and
directly plated in to chamber wells. All experiments were
performed within 7 days postisolation of macrophages.
Immunoblot analysis
Modification of HDL
High-density lipoprotein or HDL modified in vitro with
HNE, MDA, or Acro was electrophoresed by 4–15% SDS/
PAGE. Separated proteins were transferred to a nitrocellu-
lose membrane at 100 V for 1 h at 4 °C and proteins were
detected by immunoblot analysis using antibodies directed
against apoA-I (Santa Cruz) or adducts formed by HNE
(Thermo Fisher Scientific), MDA (Abcam), or Acro
(Abcam) modification.
p65 Expression
Primary peritoneal macrophages were treated with serum-
free RPMI medium (SFM) or 50 lgmL1 native HDL or
modified HDL for the time points indicated. Cells were
lysed in RIPA lysis buffer (150 mM sodium chloride, 1.0%
NP-40, 0.5% sodium deoxycholate, 0.1% SDS, and 50 mM
Tris, pH 7.5) containing protease inhibitors (1 lgmL1
pepstatin, 0.2 mM phenylmethylsulfonyl fluoride,
1 lgmL1 leupeptin, and 10 lgmL1 aprotinin) and phos-
phatase inhibitor cocktail (Sigma). Proteins were separated
by 10% SDS/PAGE and transferred to a nitrocellulose
membrane at 100 V for 1 h at 4 °C. Proteins were detected
by immunoblot analysis using antibodies directed against
phospho-p65 at residue Ser536 (Cell Signaling) or total p65
(Cell Signaling) as a loading control.
Macrophage migration
Migration of peritoneal macrophages was measured using a
Boyden Chamber assay. Briefly, peritoneal macrophages
(0.5 9 106 cells) in serum-free RPMI were placed in the
upper chamber of a 6 µm transwell insert. The inserts were
placed in wells containing SFM (RPMI 1640) or SFM with
50 µgmL1 of oxLDL, HDL, acro-HDL, HNE-HDL, or
MDA-HDL in the bottom of the wells. Cells were allowed
to migrate through the porous membrane for 24 h.
Membranes were washed twice in PBS for 5 min per wash.
Membranes were stained with DAPI and the number of
migrated cells was blindly quantified by fluorescence micro-
scopy (7–8 images per condition).
ROS generation
Primary peritoneal macrophages were cholesterol-loaded
with 50 µgmL1 oxLDL for 1 h at 37 °C in SFM. Cells
were then stimulated with SFM or SFM containing
50 µgmL1 oxLDL, HDL, acro-HDL, HNE-HDL, or
MDA-HDL for 1 h at 37 °C in the presence or absence of
500 UmL1 polyethylene glycol-catalase. At 30 min of
stimulation, 0.1 mM CBA was added in the dark for the
remaining 30 min. Cells were collected and pelleted by cen-
trifugation. The pellets were frozen at 80 °C until
required for HPLC analysis as previously described [25].
NF-jB reporter assay
Nuclear factor-kappa B reporter THP-1 cells were treated
with SFM or SFM containing 50 µgmL1 of HDL, oxLDL,
acro-, HNE-, and MDA-HDL for 1 h at 37 °C. Media was
collected and secreted alkaline phosphatase activity was mea-
sured using a colorimetric assay as described in the manufac-
turer’s protocols (InvivoGen, San Diego, CA, USA).
Inflammatory cytokine analysis
RNA isolation and quantitative RT-PCR
Primary peritoneal macrophages (some of which were pre-
treated with 50 µgmL1 oxLDL for 24 h to induce foam
cell formation) were incubated for 2, 6, or 24 h with SFM
or SFM containing native or modified forms of HDL
(50 µgmL1) at 37 °C. Total RNA was isolated from cells
using Trizol (Thermo Fisher Scientific) per manufacturer’s
instructions. cDNA was synthesized from up to 2 µg total
RNA using the reverse transcriptase MMLV and random
primers (Invitrogen). Quantitative RT-PCR was performed
using an iCycler (Biorad, Hercules, CA, USA). Relative
gene expression was determined using the 2ΔΔCt method
with the murine b-actin gene serving as the internal control.
Primer sequences are detailed in Table 1.
Table 1. Primer sequences of inflammatory-associated genes for qRT-PCR.
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Secreted cytokine levels
Primary peritoneal macrophages were cholesterol-loaded
with 50 µgmL1 oxLDL for 24 h and then incubated again
with either RPMI 1640 SFM, SFM containing 50 µgmL1
oxLDL, or SFM containing 50 lgmL1 of native or modi-
fied HDL for an additional 24 h at 37 °C. Media was col-
lected and cytokine levels were measured by ELISA using
undiluted samples per manufacturer’s protocols.
Statistics
Each experiment was repeated at least three times. Statisti-
cal analyses were determined by one-way or two-way
ANOVA with Bonferroni post hoc analyses using GRAPHPAD
PRISM7 Software (Graphpad, San Diego, CA, USA). Signifi-
cance was set at P < 0.05.
Acknowledgements
We thank Kay Nicholson for excellent technical assis-
tance and Wenxin Huang for preparation of oxLDL.
We also thank Devi Prasadh Ramakrishnan for his
intellectual contribution to the macrophage migration
experiments and Marcelo Bonini for helpful discus-
sions. This work was supported by the National Heart,
Lung, and Blood Institute at the National Institutes of
Health [R01HL58012 to DS, F31HL134280 to RLSc,
and R01HL111614 to RLSi], as well as by an Ameri-
can Heart Association Scientist Development Grant
(17SDG33661117 to YC).
Conflict of interest
All authors have read the journal’s authorship agree-
ment and policy on disclosure of potential conflict of
interest and have nothing to disclose. This article has
been reviewed and approved by all authors.
Author contributions
RLSc, RLSi, and DS conceived and designed research;
RLSc, DAK, HRP, YC, MY, and DJS performed
research and analyzed data. RLSc and DS wrote the
manuscript. All authors contributed to manuscript
editing.
References
1 Kosmas CE, DeJesus E, Rosario D & Vittorio TJ
(2016) CETP inhibition: past failures and future hopes.
Clin Med Insights Cardiol 10, 37–42.
2 Voight BF, Peloso GM, Orho-Melander M, Frikke-
Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm
H, Ding EL, Johnson T et al. (2012) Plasma HDL
cholesterol and risk of myocardial infarction: a
mendelian randomisation study. Lancet 380, 572–580.
3 Ansell BJ, Watson KE, Fogelman AM, Navab M &
Fonarow GC (2005) High-density lipoprotein function
recent advances. J Am Coll Cardiol 46, 1792–1798.
4 Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH
& Krieger M (1996) Identification of scavenger receptor
SR-BI as a high density lipoprotein receptor. Science
271, 518–520.
5 Endemann G, Stanton LW, Madden KS, Bryant CM,
White RT & Protter AA (1993) CD36 is a receptor for
oxidized low density lipoprotein. J Biol Chem 268,
11811–11816.
6 Yu XH, Fu YC, Zhang DW, Yin K & Tang CK (2013)
Foam cells in atherosclerosis. Clin Chim Acta 424, 245–
252.
7 Berliner JA & Heinecke JW (1996) The role of oxidized
lipoproteins in atherogenesis. Free Radic Biol Med 20,
707–727.
8 Ji Y, Wang N, Ramakrishnan R, Sehayek E, Huszar D,
Breslow JL & Tall AR (1999) Hepatic scavenger
receptor BI promotes rapid clearance of high density
lipoprotein free cholesterol and its transport into bile. J
Biol Chem 274, 33398–33402.
9 Terasaka N, Wang N, Yvan-Charvet L & Tall AR
(2007) High-density lipoprotein protects macrophages
from oxidized low-density lipoprotein-induced apoptosis
by promoting efflux of 7-ketocholesterol via ABCG1.
Proc Natl Acad Sci USA 104, 15093–15098.
10 Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B,
Fisher T, Sparrow CP, Taggart AK & Tall AR (2010)
Cholesterol efflux potential and antiinflammatory
properties of high-density lipoprotein after treatment
with niacin or anacetrapib. Arterioscler Thromb Vasc
Biol 30, 1430–1438.
11 Al-Jarallah A, Chen X, Gonzalez L & Trigatti BL
(2014) High density lipoprotein stimulated migration of
macrophages depends on the scavenger receptor class B,
type I, PDZK1 and Akt1 and is blocked by sphingosine
1 phosphate receptor antagonists. PLoS ONE 9,
e106487.
12 Besler C, Heinrich K, Rohrer L, Doerries C, Riwanto
M, Shih DM, Chroni A, Yonekawa K, Stein S,
Schaefer N et al. (2011) Mechanisms underlying adverse
effects of HDL on eNOS-activating pathways in
patients with coronary artery disease. J Clin Invest 121,
2693–2708.
13 Kaseda R, Jabs K, Hunley TE, Jones D, Bian A, Allen
RM, Vickers KC, Yancey PG, Linton MF, Fazio S
et al. (2014) Dysfunctional high-density lipoproteins in
children with chronic kidney disease. Metabolism 64,
263–273.
14 Smith CK, Seto NL, Vivekanandan-Giri A, Yuan W,
Playford MP, Manna Z, Hasni SA, Kuai R, Mehta
705The FEBS Journal 287 (2020) 695–707 ª 2019 Federation of European Biochemical Societies
R. L. Schill et al. Modification of HDL with reactive aldehydes
NN, Schwendeman A et al. (2017) Lupus high-density
lipoprotein induces proinflammatory responses in
macrophages by binding lectin-like oxidised low-density
lipoprotein receptor 1 and failing to promote activating
transcription factor 3 activity. Ann Rheum Dis. 76, 602–
611.
15 McMahon M, Grossman J, FitzGerald J, Dahlin-Lee
E, Wallace DJ, Thong BY, Badsha H, Kalunian K,
Charles C, Navab M et al. (2006) Proinflammatory
high-density lipoprotein as a biomarker for
atherosclerosis in patients with systemic lupus
erythematosus and rheumatoid arthritis. Arthritis
Rheum 54, 2541–2549.
16 Ellis EM (2007) Reactive carbonyls and oxidative
stress: potential for therapeutic intervention. Pharmacol
Ther 115, 13–24.
17 Conklin DJ, Barski OA, Lesgards JF, Juvan P, Rezen
T, Rozman D, Prough RA, Vladykovskaya E, Liu S,
Srivastava S et al. (2010) Acrolein consumption induces
systemic dyslipidemia and lipoprotein modification.
Toxicol Appl Pharmacol 243, 1–12.
18 Srivastava S, Conklin DJ, Liu SQ, Prakash N, Boor PJ,
Srivastava SK & Bhatnagar A (2001) Identification of
biochemical pathways for the metabolism of oxidized
low-density lipoprotein derived aldehyde-4-hydroxy
trans-2-nonenal in vascular smooth muscle cells.
Atherosclerosis 158, 339–350.
19 Tanaga K, Bujo H, Inoue M, Mikami K, Kotani K,
Takahashi K, Kanno T & Saito Y (2002) Increased
circulating malondialdehyde-modified LDL levels in
patients with coronary artery diseases and their
association with peak sizes of LDL particles.
Arterioscler Thromb Vasc Biol 22, 662–666.
20 Carnuta MG, Stancu CS, Toma L, Sanda GM,
Niculescu LS, Deleanu M, Popescu AC, Popescu MR,
Vlad A, Dimulescu DR et al. (2017) Dysfunctional
high-density lipoproteins have distinct composition,
diminished anti-inflammatory potential and discriminate
acute coronary syndrome from stable coronary artery
disease patients. Sci Rep 7, 7295.
21 Huang Y, DiDonato JA, Levison BS, Schmitt D, Li L,
Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X et al.
(2014) An abundant dysfunctional apolipoprotein A1 in
human atheroma. Nat Med 20, 193–203.
22 Holvoet P, Perez G, Zhao Z, Brouwers E, Bernar H &
Collen D (1995) Malondialdehyde-modified low density
lipoproteins in patients with atherosclerotic disease. J
Clin Invest 95, 2611–2619.
23 Chadwick AC, Holme RL, Chen Y, Thomas MJ, Sorci-
Thomas MG, Silverstein RL, Pritchard KA Jr & Sahoo
D (2015) Acrolein impairs the cholesterol transport
functions of high density lipoproteins. PLoS ONE 10,
e0123138.
24 Park YM, Febbraio M & Silverstein RL (2009) CD36
modulates migration of mouse and human macrophages
in response to oxidized LDL and may contribute to
macrophage trapping in the arterial intima. J Clin
Invest 119, 136–145.
25 Zielonka J, Zielonka M, Sikora A, Adamus J, Joseph J,
Hardy M, Ouari O, Dranka BP & Kalyanaraman B
(2012) Global profiling of reactive oxygen and nitrogen
species in biological systems: high-throughput real-time
analyses. J Biol Chem 287, 2984–2995.
26 Silverstein RL, Li W, Park YM & Rahaman SO (2010)
Mechanisms of cell signaling by the scavenger receptor
CD36: implications in atherosclerosis and thrombosis.
Trans Am Clin Climatol Assoc 121, 206–220.
27 Undurti A, Huang Y, Lupica JA, Smith JD, DiDonato
JA & Hazen SL (2009) Modification of high density
lipoprotein by myeloperoxidase generates a pro-
inflammatory particle. J Biol Chem 284, 30825–30835.
28 McLaren JE & Ramji DP (2009) Interferon gamma: a
master regulator of atherosclerosis. Cytokine Growth
Factor Rev 20, 125–135.
29 Ramji DP & Davies TS (2015) Cytokines in
atherosclerosis: key players in all stages of disease and
promising therapeutic targets. Cytokine Growth Factor
Rev 26, 673–685.
30 Singh NN & Ramji DP (2006) The role of transforming
growth factor-beta in atherosclerosis. Cytokine Growth
Factor Rev 17, 487–499.
31 Liu W, Yin Y, Zhou Z, He M & Dai Y (2014)
OxLDL-induced IL-1 beta secretion promoting foam
cells formation was mainly via CD36 mediated ROS
production leading to NLRP3 inflammasome
activation. Inflamm Res 63, 33–43.
32 Rios FJ, Ferracini M, Pecenin M, Koga MM, Wang Y,
Ketelhuth DF & Jancar S (2013) Uptake of oxLDL
and IL-10 production by macrophages requires PAFR
and CD36 recruitment into the same lipid rafts. PLoS
ONE 8, e76893.
33 Huang H, Koelle P, Fendler M, Schrottle A, Czihal M,
Hoffmann U, Conrad M & Kuhlencordt PJ (2014)
Induction of inducible nitric oxide synthase (iNOS)
expression by oxLDL inhibits macrophage derived
foam cell migration. Atherosclerosis 235, 213–222.
34 Suzuki M, Pritchard DK, Becker L, Hoofnagle AN,
Tanimura N, Bammler TK, Beyer RP, Bumgarner R,
Vaisar T, de Beer MC et al. (2010) High-density
lipoprotein suppresses the type I interferon response, a
family of potent antiviral immunoregulators, in
macrophages challenged with lipopolysaccharide.
Circulation 122, 1919–1927.
35 Robbesyn F, Auge N, Vindis C, Cantero AV, Barbaras
R, Negre-Salvayre A & Salvayre R (2005) High-density
lipoproteins prevent the oxidized low-density
lipoprotein-induced epidermal [corrected] growth factor
receptor activation and subsequent matrix
metalloproteinase-2 upregulation. Arterioscler Thromb
Vasc Biol 25, 1206–1212.
706 The FEBS Journal 287 (2020) 695–707 ª 2019 Federation of European Biochemical Societies
Modification of HDL with reactive aldehydes R. L. Schill et al.
36 DeJarnett N, Conklin DJ, Riggs DW, Myers JA,
O’Toole TE, Hamzeh I, Wagner S, Chugh A, Ramos
KS, Srivastava S et al. (2014) Acrolein exposure is
associated with increased cardiovascular disease risk. J
Am Heart Assoc 3, e000934.
37 Shao B, O’brien KD, McDonald TO, Fu X, Oram JF,
Uchida K & Heinecke JW (2005) Acrolein modifies
apolipoprotein A-I in the human artery wall. Ann NY
Acad Sci 1043, 396–403.
38 McCall MR, Tang JY, Bielicki JK & Forte TM (1995)
Inhibition of lecithin-cholesterol acyltransferase and
modification of HDL apolipoproteins by aldehydes.
Arterioscler Thromb Vasc Biol 15, 1599–1606.
39 Esterbauer H, Schaur RJ & Zollner H (1991) Chemistry
and biochemistry of 4-hydroxynonenal, malonaldehyde
and related aldehydes. Free Radic Biol Med 11, 81–128.
40 Shao B, Pennathur S, Pagani I, Oda MN, Witztum JL,
Oram JF & Heinecke JW (2010) Modifying
apolipoprotein A-I by malondialdehyde, but not by an
array of other reactive carbonyls, blocks cholesterol
efflux by the ABCA1 pathway. J Biol Chem 285,
18473–18484.
41 Weber D, Milkovic L, Bennett SJ, Griffiths HR,
Zarkovic N & Grune T (2013) Measurement of HNE-
protein adducts in human plasma and serum by
ELISA-Comparison of two primary antibodies. Redox
Biol 1, 226–233.
42 Sima A & Stancu C (2002) Modified lipoproteins
accumulate in human coronary atheroma. J Cell Mol
Med 6, 110–111.
43 Shao B, Fu X, McDonald TO, Green PS, Uchida K,
O’Brien KD, Oram JF & Heinecke JW (2005) Acrolein
impairs ATP binding cassette transporter A1-dependent
cholesterol export from cells through site-specific
modification of apolipoprotein A-I. J Biol Chem 280,
36386–36396.
44 Virella G, Derrick MB, Pate V, Chassereau C, Thorpe
SR & Lopes-Virella MF (2005) Development of capture
assays for different modifications of human low-density
lipoprotein. Clin Diagn Lab Immunol 12, 68–75.
45 Wagner P & Heinecke JW (1997) Copper ions promote
peroxidation of low density lipoprotein lipid by binding
to histidine residues of apolipoprotein B100, but they
are reduced at other sites on LDL. Arterioscler Thromb
Vasc Biol 17, 3338–3346.
46 Gerster R, Eloranta JJ, Hausmann M, Ruiz PA, Cosin-
Roger J, Terhalle A, Ziegler U, Kullak-Ublick GA, von
Eckardstein A & Rogler G (2015) Anti-inflammatory
function of high-density lipoproteins via autophagy of
IkappaB kinase. Cell Mol Gastroenterol Hepatol 1, 171–
187.e1.
47 van der Vorst EPC, Theodorou K, Wu Y, Hoeksema
MA, Goossens P, Bursill CA, Aliyev T, Huitema LFA,
Tas SW, Wolfs IMJ et al. (2017) High-density
lipoproteins exert pro-inflammatory effects on
macrophages via passive cholesterol depletion and
PKC-NF-kappaB/STAT1-IRF1 signaling. Cell Metab
25, 197–207.
48 McLaren JE, Michael DR, Ashlin TG & Ramji DP
(2011) Cytokines, macrophage lipid metabolism and
foam cells: implications for cardiovascular disease
therapy. Prog Lipid Res 50, 331–347.
49 Gargiulo S, Gamba P, Testa G, Rossin D, Biasi F, Poli
G & Leonarduzzi G (2015) Relation between TLR4/
NF-kappaB signaling pathway activation by 27-
hydroxycholesterol and 4-hydroxynonenal, and
atherosclerotic plaque instability. Aging Cell 14, 569–
581.
50 Lou Y, Liu S, Zhang C, Zhang G, Li J, Ni M, An G,
Dong M, Liu X, Zhu F et al. (2013) Enhanced
atherosclerosis in TIPE2-deficient mice is associated
with increased macrophage responses to oxidized
low-density lipoprotein. J Immunol 191, 4849–4857.
51 Bird DA, Gillotte KL, Horkko S, Friedman P, Dennis
EA, Witztum JL & Steinberg D (1999) Receptors for
oxidized low-density lipoprotein on elicited mouse
peritoneal macrophages can recognize both the
modified lipid moieties and the modified protein
moieties: implications with respect to macrophage
recognition of apoptotic cells. Proc Natl Acad Sci USA
96, 6347–6352.
52 Fujioka Y, Cooper AD & Fong LG (1998) Multiple
processes are involved in the uptake of chylomicron
remnants by mouse peritoneal macrophages. J Lipid
Res 39, 2339–2349.
53 Brundert M, Heeren J, Bahar-Bayansar M, Ewert A,
Moore KJ & Rinninger F (2006) Selective uptake of
HDL cholesteryl esters and cholesterol efflux from
mouse peritoneal macrophages independent of SR-BI. J
Lipid Res 47, 2408–2421.
54 Durham KK, Chathely KM & Trigatti BL (2018) High-
density lipoprotein protects cardiomyocytes against
necrosis induced by oxygen and glucose deprivation
through SR-B1, PI3K, and AKT1 and 2. Biochem J
475, 1253–1265.
55 Murch AR & Papadimitriou JM (1981) The kinetics of
murine peritoneal macrophage replication. J Pathol 133,
177–183.
56 Marinkovic E, Djokic R, Lukic I, Filipovic A, Inic-
Kanada A, Kosanovic D, Gavrovic-Jankulovic M &
Stojanovic M (2017) Modulation of functional
characteristics of resident and thioglycollate-elicited
peritoneal murine macrophages by a recombinant
banana lectin. PLoS ONE 12, e0172469.
57 Pavlou S, Wang L, Xu H & Chen M (2017) Higher
phagocytic activity of thioglycollate-elicited peritoneal
macrophages is related to metabolic status of the cells.
J Inflamm (Lond) 14, 4.
707The FEBS Journal 287 (2020) 695–707 ª 2019 Federation of European Biochemical Societies
R. L. Schill et al. Modification of HDL with reactive aldehydes
